TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 year old males or females~* Patients with recurrent or metastatic renal cell carcinoma (RCC) or primary RCC that is not amendable to surgical intervention~* Histologically or cytologically confirmed renal cell carcinoma~* Measurable disease~* No more than one prior systemic treatment (chemotherapy or immunotherapy) for RCC.~* No active brain metastases~* Karnofsky performance status ≥ 70%, life expectancy ≥ 3 months~* No childbearing potential, or use of effective contraception during the study and for 4 weeks after the last dose of study drug~* Archival paraffin embedded tumor tissue, if available.~* Ability to give written informed consent~Exclusion Criteria:~* Pregnant or lactating women~* Primary CNS malignancies; active CNS metastases~* Hematologic malignancies (includes: leukemia, any form; lymphoma; and multiple myeloma)~* Any of the following hematologic abnormalities:~  * Hemoglobin ≤ 9.0 g/dL~ * ANC \< 1500 per mm3~ * Platelet count \< 100,000 per mm3~* Any of the following serum chemistry abnormalities:~  * Total bilirubin \> 1.5 × the ULN~ * AST or ALT ≥ 2.5 × the ULN~ * Serum albumin \< 3.0 g/dL~ * Creatinine \> 1.7 × ULN (or calculated CLCR \<50 mL/min/1.73 m2)~ * Proteinuria \> 2.5 g/24 hours or 4+ with urine dipstick~* Significant cardiovascular disease, including:~  * Active clinically symptomatic left ventricular failure~ * Active HTN (diastolic blood pressure \> 100 mmHg). Patients with a history of hypertension must have been on stable doses of anti-hypertensive drugs for ≥ 4 weeks~ * Uncontrolled hypertension: Blood pressure \>140/90 mmHg on more than 2 antihypertensive medications.~ * Myocardial infarction within 3 months prior to administration of first study dose~* Unhealed wounds (including active gastric ulcers)~* Serious/active infection; infection requiring parenteral antibiotics~* Inadequate recovery from prior antineoplastic therapy~* Inadequate recovery from any prior surgical procedure; major surgical procedure within 4 weeks prior to study entry~* Life-threatening illness or organ system dysfunction compromising safety evaluation~* Psychiatric disorder, altered mental status precluding informed consent or necessary testing~* Inability to comply with protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
- 2 (Type: PLACEBO_COMPARATOR): solid oral capsule containing excipients dosed daily for three weeks per month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Mailed Nicotine Replacement Therapy to Canadian Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Current daily smokers who smoke 10 or more cigarettes per day~* Interested in being involved in a smoking study~* Willing to be interviewed at baseline, 8 weeks and 6 months after~* Willing to provide a saliva sample for cotinine analysis at each time point~* Interest in using nicotine patch to quit smoking~* Intent to use nicotine patch within one week of receiving it~* Willing to have nicotine patch sent to their home~Exclusion Criteria:~* Have a medical condition that would would make participation medically hazardous as determined by the list of contraindications for NRT outlined in the CPS and the NRT package insert~* Pregnant, intending on becoming pregnant, or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nicotine Replacement Therapy (Type: EXPERIMENTAL): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Electronic Health Record-Based Clinical Decision Support to Improve Blood Pressure Management in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents age 10-17~* Pediatric and Family Medicine Providers~Exclusion Criteria:~* Pregnant adolescents~* Within 12 weeks post partum

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Clinical Decision Support (CDS) (Type: EXPERIMENTAL): The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR during any visit to a family practice or pediatric clinic (including both preventive care and sick visits, excluding prenatal and postpartum visits). The algorithm will be embedded in the EHR. In most cases, when a normal BP \<90% and \<120/80 mm Hg is entered, no alerts will be triggered. In some cases, clinical staff may receive up to two alerts, either to measure height or to repeat a first elevated BP reading. In cases with confirmed elevated BP measures, providers will receive a single CDS message summarizing that patient's current BP status and recommending specific clinical actions.
- Control (Type: NO_INTERVENTION): Patients in this group will receive usual care from their clinic. The CDS tool will not be activated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Benefits of Hearing Aid Microphone Directionality Technologies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* experienced hearing aid users~* moderate to moderate severe sensorineural symmetrical hearing loss defined as a difference of less than 10 dB between ears~* must be able to use app and smart phone~Exclusion Criteria:~* asymmetrical hearing losses~* unable or unwilling to use app and smart phone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): All study participants wearing study devices and evaluating three different microphone settings in simulated noise environments in lab, and using study devices during home trial period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients meeting criteria for symptomatic myeloma~2. Patients who have progressive myeloma following initial induction (patients may have received any number of treatment regimens including prior autologous transplant)~3. Patient age 18-75 years at time of enrollment~4. Karnofsky performance status of ≥70~5. Cardiac function: LVEF \>40%~6. Hepatic: Bilirubin \<2x upper limit of normal and ALT and AST \< 2.5x the upper limit of normal~7. Renal: Creatinine clearance of \>30mL/min, estimated or calculated~8. Pulmonary: DLCO, FEV1, FVC \>50% of predicted (after correction for hemoglobin)~Exclusion Criteria:~1. Patients with diagnosis of plasma cell leukemia~2. Patients with truly non secretory myeloma (patients with light chain disease are eligible)~3. Pregnant or breast-feeding~4. Uncontrolled viral, fungal or bacterial infection Note: Infection is permitted if there is evidence of response to medication. Eligibility of HIV infected patients will be determined on a case-by-case basis.~5. Patients who have undergone prior allogeneic stem cell transplant~6. Prior solid organ transplant~7. Patients receiving prior radiation to more than 20% of bone marrow containing areas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1Total Marrow Irradiation (TMI) 3Gy (Type: EXPERIMENTAL): 3Gy with standard high dose melphalan prior to autologous stem cell rescue
- Cohort 2 Total Marrow Irradiation (TMI) 6Gy (Type: EXPERIMENTAL): 6Gy with standard high dose melphalan prior to autologous stem cell rescue
- Cohort 3 Total Marrow Irradiation (TMI) 9Gy (Type: EXPERIMENTAL): 9Gy with standard high dose melphalan prior to autologous stem cell rescue

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female older adults greater than or equal to 50 years of age~Exclusion Criteria:~* Any adult with a history of previous hepatitis B infection~* A history of vaccination with any hepatitis B vaccine~* Recent (\<72 hours) history of febrile illness (oral temperature =37.8ºC/=100.0ºF)~* Known or suspected hypersensitivity to any component of RECOMBIVAX HB™ or ENGERIX-B™ (e.g., aluminum, yeast)~* Recent administration (within 3 months prior to first injection with the study vaccine) of hepatitis B immune globulin (HBIG), serum immune globulin, or any other blood-derived product~* Receipt of licensed inactivated vaccines within 14 days prior to first injection with the study vaccine~* Receipt of licensed live virus vaccines within the 30 days prior to injection with the study vaccine~* Receipt of investigational drugs or other investigational vaccines within 3 months prior to first injection with the study vaccine~* Known or suspected impairment of immunologic function or recent use of immunomodulatory medications (e.g., systemic corticosteroids). Does not include topical and inhaled steroids~* Pregnant women, nursing mothers, and women planning to become pregnant within the study period~* Any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): RECOMBIVAX HB™
- 2 (Type: EXPERIMENTAL): Modified Process Hepatitis B Vaccine
- 3 (Type: ACTIVE_COMPARATOR): ENGERIX-B™

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Supplementation in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years.~2. Type I or II diabetic patientCKD stage 3 ( eGFR = 30 - 59 ml/min) or stage 4 ( eGFR 15-29 ml/min)~3. Proteinuria 30-300 mg/dl (microalbuminuria)~4. Low SMg levels (1.4-1.9 mg/dL; 0.58-0.78 mM) to normal (1.7-2.4 mg/dL; 0.7 -1.1 mmol/L; 1.4-2.0 mEq/L).~5. Life expectancy \>12 months.~6. Women of child-bearing age should be using contraceptives as Hormonal contraceptive or Intra-uterine device.~Exclusion Criteria:~1. Kidney donor recipient.~2. Current treatment with Mg supplements.~3. Any condition impairing intestinal absorption of Mg (e.g: chronic pancreatitis, short bowel syndrome)~4. Active malignancy.~5. Pregnancy or breastfeeding.~6. Cardiac Arrythmias.~7. Allergy towards the Mg supplement.~8. Participation in other interventional trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Magnesium arm (Type: EXPERIMENTAL): 30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
- Control (Type: ACTIVE_COMPARATOR): 30 patients will receive the standard therapy (anti-diabetic)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gastric polyp with current infection of H. pylori~* Gastric polyp size with 3mm-10mm~* Age of 20 yr - 70yr~Exclusion Criteria:~* Gastric ulcer ir duodenal ulcer (healing stage or acute stage)~* Use of PPI within 4weeks~* Liver cirrhosis, renal insufficiency, other serious chronic or acute disease~* Current infection of other bacteria, virus, or fungus~* Any cancer, psychologic disease~* Heavy drinker~* Drug abuser~* Pregnant women~* Penicillin allergy~* Use of digoxin, antifungal, wafarin~* Previous H. pylori eradication~* Gastric polyp with bleeding or malignant transformation~* Tiny polyp less than 3mm.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- eradictaion (Type: EXPERIMENTAL): H. pylori eradication group
- non-eradication (Type: NO_INTERVENTION): H. pylori non-eradication group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 25 to under 75 years~* Has smoked over 10 years on a daily basis and being a current smoker with at least 10 cig/day for at least past 5 years~* Good general health~* Intent to quit smoking~* Exhaled carbon monoxide level at least 15ppm at the baseline visit~* Strong nicotine dependence defined by Fagerström Test for Nicotine Dependence (FTND) ≥ 5 and by Heaviness of Smoking Index (HSI) ≥3~* intent to quit smoking~* prepared to follow the trial protocol and able to provide written consent.~Exclusion Criteria:~* Pregnancy or gestation or intend to get pregnant during the study follow-up~* Use of smoking cessation pharmacotherapy or ECs during the past year~* Attempt of smoking cessation by using of e-cigarettes during the past year~* Any cancer (at least five healthy follow-up years after stopping the cancer therapy)~* Instable (ischemic) vascular or heart disease~* Recent myocardial infarction in the past three months~* High blood pressure (systolic BP\> 140mmHg or diastolic 90mmHg at rest)~* History of major psychiatric depression or other psychiatric conditions and daily use of any psychiatric medicine~* Current addiction of alcohol or misuse of substance~* Inability to express himself/herself~* Known allergy to any of the study medications~* Severe allergy or poorly controlled asthma or other pulmonary disease~* Epilepsy

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Nicotine containing e-cigarettes (Type: EXPERIMENTAL): Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
- Nicotine-free e-cigarettes (Type: ACTIVE_COMPARATOR): Nicotine-free e-cigarettes + varenicline tartrate+ MI
- Motivational Interview (MI) (Type: PLACEBO_COMPARATOR): Placebo-varenicline + nicotine -free e-cigarettes + MI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Troponin positive ACS~* Successful PCI (defined as a post PCI diameter stenosis \<20% and TIMI flow ≥2)~* A planned treatment of Prasugrel for 12 months after the procedure~* written informed consent~Exclusion Criteria:~* Age \<18 years and \>80 years~* Subjects with known contraindications to Clopidogrel treatment, which are hypersensitivity to the drug substance or any component of the product and active pathological bleeding such as peptic ulcer or intracranial hemorrhage~* Subjects with known contraindications to Prasugrel treatment, which are hypersensitivity to the drug substance or any component of the product, active pathological bleeding such as peptic ulcer or intracranial hemorrhage and a history of prior transient ischemic attack (TIA) or stroke~* Cardiogenic shock~* Subjects requiring concomitant treatment with an anticoagulant agent (Vitamin-K antagonists or novel oral anticoagulants such as Rivaroxaban, Dabigatran or Apixaban)~* Indication for major surgery (per decision of the treating physician) for the planned duration of the study~* Simultaneous participation in another clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 30 days prior to clinical trial beginning~* Known or persistent abuse of medication, drugs or alcohol~* Current or planned pregnancy or nursing women, women 90 days after childbirth. Females of childbearing potential, who do not use and are not willing to use medically reliable methods of contraception for the entire study duration (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases~* Evidence of significant active neuropsychiatric disease, in the investigator's opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: ACTIVE_COMPARATOR): Prasugrel 5 mg or 10mg daily for 12 months.
- Prasugrel/Clopidogrel (Type: EXPERIMENTAL): Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have completed the 15 days of Pasireotide treatment in the CSOM230B2208 study and have achieved normalization of 24-hour urinary free cortisol. Participants who did not achieve normalization of 24 -hour urinary free cortisol may be enrolled if in the opinion of the investigator the participant is getting significant clinical benefits from treatment with Pasireotide .~* The participant did not experience any unacceptable adverse events of tolerability issues during the original 15 day treatment.~* Female participants of childbearing potential who have not undergone clinically documented total hysterectomy and/or ovariectomy or tubal ligation must agree to use barrier contraception throughout the course of the extension study, and for one month after the study has ended.~Exclusion Criteria:~* Participant who have developed poorly controlled diabetes mellitus as indicated by ketoacidosis or hemoglobin (Hgb) A1C (HgbA1C) \> 10 since starting \[study CSOM230B2208\].~* Participant with persistent alanine aminotransferase (ALT)/ aspartate transaminase (AST) or alkaline phosphatase levels more than 2.5X upper limit of normal (ULN), serum creatinine \> 2.0 X ULN, serum bilirubin \> 2 X ULN.~* Participant with abnormal coagulation (Prothrombin time (PT) and partial thromboplastin time (PTT) elevated by 30% above normal limits), white blood cells (WBC) \<3.0x1'000'000'000/L; Hgb \<12.0g/dL for females, Hgb \<13.0g/dL for males; PLT \<100x1'000'000'000/L.~Other protocol-defined inclusion / exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pasireotide 600 μg BID SC or Ramp up Dose 900 μg BID SC (Type: EXPERIMENTAL): Participants received pasireotide 600 micrograms (μg) twice daily (BID) subcutaneously (SC) to achieve or maintain urinary free cortisol (UFC) normalization. If UFC levels were increased at any time, participants received 900 μg BID SC, until no safety or tolerability concerns were observed as per investigators assessment. If the participant was unable to tolerate the 900 μg BID, dosing of 600 μg three times a day was given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 19 yr of age scheduled to undergo liver transplantation.~Exclusion Criteria:~* Patients \< 19 yr of age~* Patients undergoing re-transplantation or dual organ transplantation~* Patients with underlying pulmonary complications

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1. Experimental (Type: EXPERIMENTAL): iNO administration
- 2. Placebo (Type: PLACEBO_COMPARATOR): Placebo (nitrogen)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete